

Board of examiners

Prof. Dr. Jorma Ilonen

Institute of Biomedicine
University of Turku, Turku, Finland

Prof. Dr. Laurent Crenier

Department of Endocrinology
Hôpital Erasme, ULB, Brussels, Belgium

Prof. Dr. Christian Demanet

Department of Molecular Hematology
UZ Brussel, VUB, Brussels, Belgium

Prof. Dr. Daniël Jacobs-Tulleneers-Thevissen

Diabetes Research Center
VUB, Brussels, Belgium

Prof. Dr. Brigitte Velkeniers, Chair

Department of Internal Medicine and Endocrinology
UZ Brussel, Vrije Universiteit Brussel

Prof. Dr. Bart J. Van der Auwera, Promoter

Diabetes Research Center
Vrije Universiteit Brussel

Prof. Dr. Bart Keymeulen, Promoter

Diabetes Research Center & Diabetes Clinic
UZ Brussel, Vrije Universiteit Brussel

Prof. Dr. Frans K. Gorus, Promoter

Diabetes Research Center & Laboratory of Clinical Chemistry and Radio-Immunology
UZ Brussel, Vrije Universiteit Brussel



PhD in Medical Sciences
2017-2018

INVITATION to the Public defence of

Else M. BALKE

To obtain the academic degree of '**DOCTOR IN MEDICAL SCIENCES**'

Gene polymorphisms and clinical outcome at various stages of (pre)type 1 diabetes.

Thursday 6 September 2018

Auditorium **Vanden Driessche** 17:00
Faculty of Medicine and Pharmacy, Laarbeeklaan 103, 1090 Brussel

How to reach the campus Jette:

<http://www.vub.ac.be/english/infoabout/campuses>

Summary of the dissertation

Type 1 diabetes (T1D) is a chronic autoimmune disease leading to ablation of pancreatic beta cells and insulin deficiency. In the absence of a genuine cure, the patients depend on lifelong insulin replacement therapy to delay the onset chronic complications. The global incidence is rising annually, calling for prevention strategies aiming to impede the destruction of beta-cells or restore functional beta cell mass. In this context, we focussed on the role of genetic markers to predict clinical outcome at various stages of T1D. Given the strong inter-individual disease heterogeneity, current prediction models for T1D, based on HLA class II haplotypes and autoantibodies, need to be further refined. Several reports have associated the HLA class I alleles *A*24*, *B*18* and/or *B*39* with increased disease risk as well. However, their impact on the various asymptomatic stages of T1D, is less well documented. In a large cohort of islet autoantibody positive relatives of T1D patients followed for up to 20 years we showed that unlike HLA class II risk haplotypes, *A*24* and *B*18* accelerated progression to clinical onset from the stage of multiple autoantibody positivity on.

Next, we investigated whether these HLA class I alleles could also help predict graft outcome after islet cell allotransplantation in long-standing T1D patients. Retrospective analysis of data from a hospital-based patient cohort showed that *A*24* carriership hampers achievement of insulin independence. However, less than half of those who failed to achieve this endpoint, carried the allele. We subsequently identified presence of the T allele at rs13266634 of the *SLC30A8* gene and high BMI as additional recipient factors associated with poor functional outcome. These findings may assist in the planing and interpretation of new intervention trials.

Curriculum Vitae

Else Marieke Balke was born in Deventer, the Netherlands, on August 21st in 1988. She attended secondary school at the 'Bisschoppelijk College' in Echt and majored in Nature, Science and Health. In 2007, she started a Bachelor of Pharmaceutical Sciences at the Catholic University of Leuven (KUL) and subsequently obtained her master's degree in Drug Development and the title of Pharmacist. In 2012, she started working as a Graduate Teaching Assistant in Chemistry and Biochemistry at the Medical School of the Brussels Free University (VUB) and enrolled in the doctoral programme of Life Sciences and Medicine. Since then, she is conducting research at the Diabetes Research Center of the VUB on a project focussed on genetic markers of type 1 diabetes.